416 related articles for article (PubMed ID: 29614779)
21. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.
Rolland M; Gilbert P
AIDS Res Hum Retroviruses; 2012 Apr; 28(4):400-4. PubMed ID: 21902593
[TBL] [Abstract][Full Text] [Related]
22. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.
Excler JL; Ake J; Robb ML; Kim JH; Plotkin SA
Clin Vaccine Immunol; 2014 Aug; 21(8):1023-36. PubMed ID: 24920599
[TBL] [Abstract][Full Text] [Related]
23. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.
Rademeyer C; Korber B; Seaman MS; Giorgi EE; Thebus R; Robles A; Sheward DJ; Wagh K; Garrity J; Carey BR; Gao H; Greene KM; Tang H; Bandawe GP; Marais JC; Diphoko TE; Hraber P; Tumba N; Moore PL; Gray GE; Kublin J; McElrath MJ; Vermeulen M; Middelkoop K; Bekker LG; Hoelscher M; Maboko L; Makhema J; Robb ML; Abdool Karim S; Abdool Karim Q; Kim JH; Hahn BH; Gao F; Swanstrom R; Morris L; Montefiori DC; Williamson C
PLoS Pathog; 2016 Jul; 12(7):e1005742. PubMed ID: 27434311
[TBL] [Abstract][Full Text] [Related]
24. Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination.
Martinez DR; Permar SR; Fouda GG
Clin Vaccine Immunol; 2016 Feb; 23(2):84-94. PubMed ID: 26656117
[TBL] [Abstract][Full Text] [Related]
25. HIV/AIDS Vaccines: 2018.
Robinson HL
Clin Pharmacol Ther; 2018 Dec; 104(6):1062-1073. PubMed ID: 30099743
[TBL] [Abstract][Full Text] [Related]
26. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
27. Immunological mechanisms of inducing HIV immunity in infants.
Fouda GG; De Paris K; Levy O; Marchant A; Gray G; Permar S; Marovich M; Singh A
Vaccine; 2020 Jan; 38(3):411-415. PubMed ID: 31761501
[TBL] [Abstract][Full Text] [Related]
28. HIV Vaccine Efficacy Trials: RV144 and Beyond.
Heger E; Schuetz A; Vasan S
Adv Exp Med Biol; 2018; 1075():3-30. PubMed ID: 30030787
[TBL] [Abstract][Full Text] [Related]
29. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
O'Connell RJ; Kim JH; Excler JL
Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
[TBL] [Abstract][Full Text] [Related]
30. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.
Wren L; Kent SJ
Hum Vaccin; 2011 Apr; 7(4):466-73. PubMed ID: 21389779
[TBL] [Abstract][Full Text] [Related]
31. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
[TBL] [Abstract][Full Text] [Related]
32. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
[TBL] [Abstract][Full Text] [Related]
33. Tiny steps towards an HIV vaccine.
Willyard C
Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706
[No Abstract] [Full Text] [Related]
34. In vivo protection by broadly neutralizing HIV antibodies.
van Gils MJ; Sanders RW
Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
[TBL] [Abstract][Full Text] [Related]
35. Lessons learned from human HIV vaccine trials.
Pollara J; Easterhoff D; Fouda GG
Curr Opin HIV AIDS; 2017 May; 12(3):216-221. PubMed ID: 28230655
[TBL] [Abstract][Full Text] [Related]
36. The Antibodiome-Mapping the Humoral Immune Response to HIV.
Butler AL; Fischinger S; Alter G
Curr HIV/AIDS Rep; 2019 Apr; 16(2):169-179. PubMed ID: 30903381
[TBL] [Abstract][Full Text] [Related]
37. [Advances in the Immunogenic Design of HIV-1 Vaccine].
Zhang X; Wang T; Yu X
Bing Du Xue Bao; 2016 Jan; 32(1):88-92. PubMed ID: 27295889
[TBL] [Abstract][Full Text] [Related]
38. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
[TBL] [Abstract][Full Text] [Related]
39. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
[TBL] [Abstract][Full Text] [Related]
40. Early Pro-Inflammatory Signal and T-Cell Activation Associate With Vaccine-Induced Anti-Vaccinia Protective Neutralizing Antibodies.
Hou J; Wang S; Li D; Carpp LN; Zhang T; Liu Y; Jia M; Peng H; Liu C; Wu H; Huang Y; Shao Y
Front Immunol; 2021; 12():737487. PubMed ID: 34707608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
